


PHARMACEUTICAL 2012

Aegerion Pharmaceuticals Inc
Rank 131 of 196



The relative strengths and weaknesses of Aegerion Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aegerion Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Aegerion Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 129% points.

The company's Economic Capital Ratio, given in the ranking table, is 154%, being 80% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	74,077
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,400
Liabilities, Non-Current	0
Other Assets	965
Other Compr. Net Income	0
Other Expenses	9,596
Other Liabilities	8,966
Other Net Income	3,686
Other Revenues	0
Property and Equipment	526
Research and Development	73,558
Selling, General and Administrative Expense	39,254

Output Variable	Value in 1000 USD
Assets	75,568
Liabilities	18,367
Expenses	122,408
Revenues	0
Stockholders Equity	57,201
Net Income	-118,722
Comprehensive Net Income	-118,722
BaseVar	110,014
ECR before LimitedLiability	13%
Economic Capital Ratio	154%